LICENSE AGREEMENTLicense Agreement • February 26th, 2004 • Pharmaceutical Product Development Inc • Services-commercial physical & biological research • California
Contract Type FiledFebruary 26th, 2004 Company Industry Jurisdiction
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. TERMINATION AND LICENSE AGREEMENTTermination and License Agreement • February 26th, 2004 • Pharmaceutical Product Development Inc • Services-commercial physical & biological research • Indiana
Contract Type FiledFebruary 26th, 2004 Company Industry JurisdictionTHIS TERMINATION AND LICENSE AGREEMENT (“Agreement”), effective as of December 18, 2003 (“Effective Date”), is made by and among Eli Lilly and Company, a corporation organized under the laws of the State of Indiana, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana, 46285 (hereinafter “Lilly”), Pharmaceutical Product Development, Inc., a corporation organized under the laws of the State of North Carolina (hereinafter “PPD”), GenuPro, Inc., a wholly-owned subsidiary of PPD, and a corporation organized under the laws of North Carolina (hereinafter “GenuPro”) and APBI Holdings, LLC, a wholly-owned subsidiary of PPD, and a limited liability company organized under the laws of North Carolina (hereinafter “APBI Holdings”). (Each party to this Agreement is hereinafter referred to as a “Party”, or collectively, the “Parties.” All references to a Party shall be deemed to include that Party’s Affiliates).
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. Amendment No. 1 To LICENSE AGREEMENTLicense Agreement • February 26th, 2004 • Pharmaceutical Product Development Inc • Services-commercial physical & biological research
Contract Type FiledFebruary 26th, 2004 Company IndustryThis Amendment No. 1 to License Agreement (“Amendment No. 1”) is effective as of the 26th day of December, 2003 (the “Amendment Effective Date”) by and among Pharmaceutical Product Development, Inc., a North Carolina corporation having a place of business at 3151 South Seventeenth Street, Wilmington, NC 28412 (hereinafter “PPD”) and its wholly owned subsidiary GenuPro, Inc., d/b/a PPD GenuPro, a North Carolina corporation having a place of business at 3900 Paramount Parkway, Morrisville, North Carolina 27560 (hereinafter “GenuPro”), and ALZA Corporation, a Delaware corporation having a place of business at 1900 Charleston Road, Mountain View, CA 94043 (hereinafter “Licensee”). PPD, GenuPro and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. COLLABORATION AGREEMENTCollaboration Agreement • February 26th, 2004 • Pharmaceutical Product Development Inc • Services-commercial physical & biological research • North Carolina
Contract Type FiledFebruary 26th, 2004 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (the “Agreement”) is entered into and made effective as of November 19, 2003 (the “Effective Date”) by and between SYRRX, INC., a Delaware corporation having its principal place of business at 10410 Science Center Drive, San Diego, CA 92121 (“Syrrx”), and DEVELOPMENT PARTNERS, LLC, a Delaware limited liability company having its principal place of business at 3151 South 17th Street, Wilmington, NC 28412 (“PPD”), a wholly owned subsidiary of PHARMACEUTICAL PRODUCT DEVELOPMENT, INC., a North Carolina corporation having its principal place of business at 3151 South 17th Street, Wilmington, NC 28412 (“PPD, Inc.”). Syrrx and PPD are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” PPD, Inc. is a party to this Agreement solely for purposes of Sections 17.18 and 17.19.